Medical/Pharmaceuticals

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lami...

2021-08-03 21:00 2486

Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), and GaoRong Capital

NANJING, China, Aug. 3, 2021 /PRNewswire/ -- Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed, Cenova, Lilly Asia Ventures (LAV), and GaoRong Capital. Funds raised in this round w...

2021-08-03 20:32 2420

CartiHeal Announces Pivotal Study Results Demonstrate Agili-C™ Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects

According to a Two-Year Randomized and Controlled Multinational IDE Study KFAR SABA, Israel, Aug. 3, 2021 /PRNewswire/ -- CartiHeal Ltd, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, which was granted Breakthrough Device...

2021-08-03 20:06 2374

111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China

SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced a strategic cooperation agreement with Suzhou Zelgen ...

2021-08-03 20:00 8204

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...

2021-08-03 20:00 5796

TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert

GUANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- The latest research findings from the team of Professor Yang Zifeng from the State Key Laboratory of Respiratory Disease inGuangzhou, China, have showed that Chinese medicine Lianhua Qingwen has an effective inhibitory action on the Delta variant of ...

2021-08-03 15:27 2992

Nanoform and Boehringer Ingelheim execute master services agreement

HELSINKI, Aug. 3, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development proj...

2021-08-03 14:28 2640

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor

BEIJING, Aug. 3, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to target t...

2021-08-03 09:00 4447

CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA and considered for Priority Review

* Ivosidenib (TIBSOVO®, the brand name in the U.S.) is the first isocitrate dehydrogenase 1 (IDH1) inhibitor inChina that has demonstrated its efficacy and manageable safety in patients with relapsed or refractory acute myeloid leukemia (R/R AML) * The National Medical Products Administration...

2021-08-03 08:05 4395

Insilico Medicine and Westlake Pharma Announce Cooperation Relationship on Accelerating the Innovative Drugs R&D for Novel Coronavirus

HANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- Insilico Medicine and Westlake Pharma announced a strategic partnership to jointly develop innovative small-molecule drugs for Novel Coronavirus (COVID-19) today. Insilico Medicin...

2021-08-03 08:00 35567

Cardinal Health completes sale of Cordis business to Hellman & Friedman

DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The sale price of approximately$1 billion includes the buyer's assumption of certain lia...

2021-08-02 23:00 3822

Cardinal Health completes sale of Cordis business to Hellman & Friedman

DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The sale price of approximately$1 billion includes the buyer's assumption of certain lia...

2021-08-02 23:00 4183

SI Group Ranks in the Top 5 Percent for Global Corporate Social Responsibility

Company Awarded Gold Rating by EcoVadis for its Sustainability Commitment SCHENECTADY, N.Y., Aug. 2, 2021 /PRNewswire/ -- SI Group, a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates, has received...

2021-08-02 22:33 3268

Vision Impact Institute Applauds UN Resolution on Vision

Resolution highlights impact of good vision to achieving the Sustainable Development Goals DALLAS, Aug. 2, 2021 /PRNewswire/ -- The Vision Impact Institute applauds the UN General Assembly's adoption of theVision for Everyone: accelerating action to achieve the Sustainable Development Goals reso...

2021-08-02 22:30 2626

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP c...

2021-08-02 20:13 4162

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

* Nitric oxide has antimicrobial properties with direct proven effect on SARS-CoV-2 * Nitric Oxide Nasal Spray (NONS) has been tested in healthy volunteers and patients as part of UK andCanada clinical trials1 MUMBAI, India and VANCOUVER, BC, Aug. 2, 2021 /PRNewswire/ -- Glenmark Pharmaceutic...

2021-08-02 18:45 3991

ElectroPhysiology Frontiers announces appointment of Avi Fischer, M.D. as CEO

MILAN, Aug. 2, 2021 /PRNewswire/ -- ElectroPhysiology Frontiers S.p.A. (EPF), announced that its Board of Directors unanimously appointedAvi Fischer, M.D. as Chief Executive Officer (CEO) of the company and a member of its Board of Directors. EPF is a medical technology company developing an inn...

2021-08-02 18:00 2640

Bionomics Announces Plans to Conduct U.S. Initial Public Offering

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...

2021-08-02 18:00 14395

Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers

HOUSTON and SINGAPORE, Aug. 2, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

2021-08-02 17:00 1819

BIOKANGTAI COVID-19 Vaccine Approved for Phase III Clinical Trial in the Philippines

SHENZHEN, China, Aug. 2, 2021 /PRNewswire/ -- On July 30, Shenzhen Kangtai Biological Products Co., Ltd. (BIOKANGTAI) was approved by the Philippine Food and Drug Administration (PFDA) to launch the phase III clinical trial of its independently developed Inactivated COVID-19 Vaccine (Vero cells) ...

2021-08-02 15:25 5827
1 ... 587588589590591592593 ... 644